Clinical trial NCT00003215 (phase 3, status: completed)
Conditions: lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: chop regimen, cyclophosphamide, cytarabine, doxorubicin hydrochloride, etoposide, leucovorin calcium, melphalan, methotrexate, methylprednisolone, mitoxantrone hydrochloride, prednisone, therapeutic hydrocortisone, vincristine sulfate
SMILES: CCO, ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1, NC1=NC(=O)C2=C(NC[C@H](CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N2C=O)N1, N[C@@H](CC1=CC=C(C=C1)N(CCCl)CCCl)C(O)=O, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C, OCCNCCNC1=CC=C(NCCNCCO)C2=C1C(=O)C1=C(C(O)=CC=C1O)C2=O, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C, [H][C@@]12CC[C@](O)(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C, CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed aggressive non-Hodgkin's lymphoma (NHL)

               -  Diffuse large B-cell lymphoma

               -  Primary mediastinal large B-cell lymphoma

               -  Anaplastic large cell lymphoma (B-cell, T-cell, or null-cell type)

          -  At least two of the following risk factors:

               -  Stage III or IV

               -  LDH greater than upper limit of normal (ULN)

               -  ECOG 2, 3, or 4

          -  No CNS involvement

        PATIENT CHARACTERISTICS:

        Age:

          -  18 to 60

        Performance status:

          -  See Disease Characteristics

          -  ECOG 0-4

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  Not specified

        Hepatic:

          -  No hepatitis B or C

          -  AST or ALT no greater than 2 times ULN*

          -  Bilirubin no greater than 2.34 mg/dL* NOTE: *Unless due to tumor involvement

        Renal:

          -  Creatinine clearance at least 60 mL/min (unless due to tumor involvement)

        Cardiovascular:

          -  No significant heart failure

          -  LVEF normal

          -  No active angina pectoris

          -  No myocardial infarction within the past 6 months

          -  No major ventricular arrhythmia

        Pulmonary:

          -  No significant lung disorder

        Other:

          -  HIV negative

          -  No severe active acute or chronic infection

          -  No severe psychoses

          -  No prior or concurrent malignancy except adequately treated carcinoma in situ of the
             cervix or nonmelanomatous skin cancer

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  No prior chemotherapy for NHL (except emergency therapy, but no more than 1 course of
             standard chemotherapy)

        Endocrine therapy:

          -  Not specified

        Radiotherapy:

          -  No prior radiotherapy for NHL (except emergency therapy of no greater than 600 cGy
             radiation)

          -  No concurrent prophylactic radiotherapy to the brain

        Surgery:

          -  Not specified